

CHINESE JOURNAL OF NEPHROLOGY

Monthly Established in March 1985 Volume 39, Number 11 November 15, 2023

Responsible Institution

China Association for Science
and Technology

Sponsor

Chinese Medical Association
42 Dongsi Xidajie, Beijing 100710, China

Editing

Editorial Board of Chinese Journal of
Nephrology
58 Zhongshan Road II, Guangzhou 510080, China
Tel: 0086-20-87331532
Email: cmaszb@mail.sysu.edu.cn
http://www.medjournals.cn
http://www.cjn.org.cn

Editor-in-Chief

Yu Xueqing(余学清)

Managing Director

Wang Xin(王欣)

Publishing

Chinese Medical Journals
Publishing House Co., Ltd.
42 Dongsi Xidajie, Beijing 100710, China
Tel(Fax): 0086-10-51322059
Email: office@cmaph.org

Printing

Guangzhou BaoCheng Printing Co., Ltd.

Overseas Distributor

China International Book
Trading Corporation
P. O. Box 399, Beijing 100044, China
Code No. M86

Mail-Order

Editorial Board of Chinese
Journal of Nephrology
58 Zhongshan Road II, Guangzhou 510080, China
Tel: 0086-20-87331532

CSSN

ISSN 1001-7097
CN 44-1217/R

Copyright © 2023 by the Chinese Medical Association

No content published by the journals of Chinese
Medical Association may be reproduced or
abridged without authorization. Please do not use
or copy the layout and design of the journals
without permission.

All articles published represent the opinions of
the authors, and do not reflect the official policy
of the Chinese Medical Association or the
Editorial Board, unless this is clearly specified.

CONTENTS IN BRIEF

Clinical Study

Association of body mass index and waist circumference with risk of all-cause mortality in middle-aged and elderly patients

receiving maintenance hemodialysis 809

Shi Zhihua, Guo Yidan, Zhang Chunxia, Zhou Xiaoling, Ye Pengpeng,

Luo Yang

Analysis of risk factors of sarcopenia in maintenance

hemodialysis patients 815

Li Hong, Chen Ruman, Zeng Xin, Bai Yafei, Xu Mingzhi, Li Jifeng,

Wen Gongxiong, Wang Chaoqun

Urinary microalbumin to creatinine ratio and α 1-microglobulin

to creatinine ratio and their influencing factors

in people aged ≥ 40 years old in 10 counties

of Shanxi province 822

Song Wenzhu, Zhao Yan, Qiu Lixia, Zhang Chao, Zhang Yue, Han Huimin,

Li Aizhong, Zhou Xiaoshuang, Li Yafeng, Li Rongshan

Correlation between urinary exosomal miR-155 and the onset

and severity of type 2 diabetic kidney disease

..... 831

Huang Hongyan, Tan Fang, Lu Yan, Shi Feiyan, Ding Jia

Basic Study

Removal of anti-phospholipase A2 receptor autoantibodies in primary membranous nephropathy by recombinant phospholipase A2

receptor tandem epitope immunosorbent 840

Wang Kexin, Liu Shuxin, Ji Fangling, Qian Jiahang, Ren Jun,

Han Lulu, Jia Lingyun

Short Original Article

Risk factors of death and construction of a survival prediction model

in maintenance hemodialysis patients with corona virus

disease 2019 846

Shi Qihong, Jiang Shan, Gao Luyan, Zeng Ying, Liu Lingling,

Feng Sheng, Zhi Jia, Song Kai

Case Report

- Overlap syndrome: a case report of extensive chronic graft-versus-host disease and literature review**
..... 851
*Zhou Yanxia, Luo Shenghui, Qin Weixuan, Ye Hongjian, Wang Ying, Chen Wenfang,
Li Zhijian, Chen Wei, Wang Xin*
- A case report and literature review of rhabdomyolysis and acute kidney injury caused
by SARS-CoV-2 infection** 857
Wang Wei, Li Yuehong, Xu Huiying

Review

- An overview of clinical studies on SARS-CoV-2 infection in dialysis patients**
..... 860
Li Zuolin, Pan Mingming, Wang Guihua, Yin Qing, Shen Anran, Yang Qin, Liu Bicheng
- Advances of chronic kidney disease-mineral and bone disorder**
..... 867
Yao Lan, Wang Pei

Guide Interpretation

- Interpretation of 2022 IPNA clinical practice recommendation for the diagnosis and management in children
with steroid-sensitive nephrotic syndrome and comparison with 2016 guideline of China**
..... 872
Zhang Pei, Gao Chunlin, Yao Jun, Xia Zhengkun

Expert Consensus

- Chinese expert consensus on the clinical application of sodium-glucose transporter 2 inhibitors
in patients with chronic kidney disease (2023 edition)**
..... 879
*Expert group of Chinese expert consensus on the clinical application of sodium-glucose transporter 2 inhibitors
in patients with chronic kidney disease (2023 edition)*